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Summary for Twitter: This LEADER analysis showed fewer major cardiovascular events 
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Background: More data regarding effects of glucagon-like peptide-1 receptor agonists in 
patients with type 2 diabetes (T2D) and heart failure (HF) are required. 
Objectives: To investigate effects of liraglutide on cardiovascular events and mortality in 
LEADER participants, by HF history.  
Methods: In the multinational, double-blind, randomized LEADER trial (ClinicalTrials.gov: 
NCT01179048), 9340 patients with T2D and high cardiovascular risk were assigned 1:1 to 
liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily) or placebo plus 
standard care, and followed for 3.5–5 years. New York Heart Association (NYHA) class IV 
HF was an exclusion criterion. The primary composite major adverse cardiovascular events 
(MACE) outcome was time to first occurrence of cardiovascular death, non-fatal myocardial 
infarction or non-fatal stroke. Post hoc Cox regression analyses of outcomes by baseline HF 
history were conducted. 
Results: At baseline, 18% of patients had a history of NYHA class I–III HF (liraglutide, N = 
835/4668; placebo: N = 832/4672). Effects of liraglutide versus placebo on MACE were 
consistent in patients with (hazard ratio [HR; 95% confidence interval CI]: 0.81 [0.65; 1.02]) 
and without (0.88 [0.78; 1.00]) a history of HF (p-interaction = 0.53). In both subgroups, 
fewer deaths were observed with liraglutide (0.89 [0.70; 1.14] with HF; 0.83 [0.70; 0.97] 
without HF; p-interaction = 0.63), versus placebo. No increased risk of HF hospitalization 
was observed with liraglutide, regardless of HF history (0.98 [0.75; 1.28] with HF; 0.78 
[0.61; 1.00] without HF; p-interaction = 0.22). Effects of liraglutide on the composite of HF 
hospitalization or cardiovascular death were consistent in patients with (0.92 [0.74; 1.15]) 
and without (0.77 [0.65; 0.91]) a history of HF (p-interaction = 0.19). 
Conclusions: Based on these findings, liraglutide should be considered suitable for patients 




Different glucose-lowering therapies have varying effects on heart failure (HF) outcomes. 
This analysis investigated effects of the glucagon-like peptide-1 analog liraglutide on 
cardiovascular events and mortality in LEADER trial participants with/without New York 
Heart Association (NYHA) class I–III HF at baseline (class IV excluded). Its results showed 
fewer major adverse cardiovascular events, fewer deaths and no increased risk of HF 
hospitalization with liraglutide versus placebo, regardless of baseline HF status. This analysis 
indicates that liraglutide should be considered a suitable treatment option for patients with 
type 2 diabetes, with/without a history of NYHA class I–III HF. 
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DPP-4is = dipeptidyl peptidase-4 inhibitors 
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Different glucose-lowering therapies have varying effects on heart failure (HF) outcomes. 
Studies of the thiazolidinediones rosiglitazone and pioglitazone and the dipeptidyl peptidase-
4 inhibitor (DPP-4i) saxagliptin have indicated an increase in the risk of HF events or HF 
hospitalization in patients with type 2 diabetes (T2D) (1-3), whereas the sodium-glucose 
cotransporter-2 inhibitors empagliflozin, canagliflozin and dapagliflozin reduce this risk (4-
6). 
 
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to treat patients 
with T2D (7). Cardiovascular outcomes trials have demonstrated cardiovascular safety of the 
GLP-1RAs lixisenatide, once-weekly exenatide and oral semaglutide (which showed non-
inferiority versus placebo for major adverse cardiovascular events [MACE]), and 
cardiovascular risk reduction with liraglutide, subcutaneous semaglutide, albiglutide and 
dulaglutide versus placebo in patients with T2D (8-15). Albiglutide reduced the risk of HF 
hospitalization versus placebo in the Harmony Outcomes trial (15); in the remaining trials, no 
significant differences in risk of HF hospitalization were reported with GLP-1RAs versus 
placebo (8-15). More data are required to establish whether these benefits are observed in 
patients with HF or whether these patients are at a higher risk of such events when treated 
with a GLP-1RA. While some previous small studies with liraglutide in patients with HF 
showed improvements in left ventricular function (16,17), others indicated potential safety 
concerns in patients with HF with reduced ejection fraction (18,19).  
 
The LEADER cardiovascular outcomes trial evaluated effects of liraglutide (1.8 mg daily or 
maximum tolerated dose up to 1.8 mg daily) versus placebo in patients with T2D and high 




Association (NYHA) class II–III chronic HF was one of several possible cardiovascular risk 
enrichment criteria and was used to define pre-specified subgroups (with/without chronic HF) 
(12). HF requiring hospitalization was among the adjudicated endpoints captured during 
treatment exposure and follow-up (12). 
 
This analysis investigated effects of liraglutide versus placebo on cardiovascular events 
(including HF hospitalization), all-cause death, nephropathy and heart rate in LEADER trial 
participants, stratified by HF history (NYHA class I–III). We also investigated the influence 
of prior atherosclerotic events on risk of HF hospitalization with liraglutide versus placebo. 
 
Methods 
The design of the multinational, double-blind, LEADER cardiovascular outcomes trial 
(NCT01179048) has been detailed elsewhere (12). The protocol was approved by the relevant 
independent ethics committee or institutional review board for each study site. The protocol 
and details of the 410 study sites have been published previously (12). All participants 
provided written informed consent. 
 
LEADER included patients with T2D aged ≥50 years with either established cardiovascular 
disease or chronic kidney disease, or aged ≥60 years with ≥1 cardiovascular risk factor. 
Chronic NYHA class IV HF was an exclusion criterion. HF history and NYHA class were 
based on medical history as reported by the trial investigator for each patient. Information 
relating to inclusion/exclusion criteria and to HF, including NYHA class, was recorded in a 





Participants were randomized 1:1 to receive once-daily, subcutaneous liraglutide 1.8 mg (or 
maximum tolerated dose up to 1.8 mg) or placebo, both plus standard care, and followed for 
3.5–5 years. For patients not meeting their glycated hemoglobin target, the addition of 
glucose-lowering medications was permitted after randomization, except for GLP-1RAs, 
DPP-4is or pramlintide. A global expert panel developed standard of care treatment 
guidelines to encourage investigators to manage individual participant’s blood glucose, blood 
pressure and lipid levels, and to guide concomitant therapy. Use of concomitant medications 
(e.g. for management of cardiovascular risk factors and events such as HF hospitalization) 
was at the investigator’s discretion, according to local practices and regulations. 
 
The primary endpoint was time from randomization to the first occurrence of a composite 
MACE outcome consisting of cardiovascular death, non-fatal (including silent) myocardial 
infarction (MI) or non-fatal stroke. Pre-specified secondary endpoints included time from 
randomization to the first occurrence of: an expanded composite outcome that additionally 
included coronary revascularization or hospitalization for unstable angina pectoris or HF 
(expanded MACE); individual components of the expanded MACE outcome; all-cause death; 
and a composite nephropathy endpoint (new-onset macroalbuminuria, persistent doubling of 
serum creatinine level and creatinine clearance ≤45 mL/min/1.73m2 per Modification of Diet 
in Renal Disease equation, need for continuous renal-replacement therapy [in the absence of 
an acute reversible cause], or death due to renal disease). An external, independent, blinded 
event adjudication committee adjudicated all potential cardiovascular events (including HF 
requiring hospitalization) and all deaths. The definitions used for these events have been 
published previously (12). The definition of adjudicated HF hospitalization is provided in the 
Online Appendix. The composite outcomes of time to first HF hospitalization or all-cause 






Exploratory analyses of the primary and secondary outcomes by chronic HF subgroups were 
pre-specified (12), but the present analyses were conducted post hoc. Presence or absence of 
HF at screening was recorded for all randomized participants (N = 9340). We evaluated the 
risk of cardiovascular events, all-cause death and nephropathy observed with liraglutide 
versus placebo in LEADER participants with or without a history of HF (NYHA class I–III) 
at baseline. The analysis used the full analysis set and a Cox regression model with treatment, 
HF history and the interaction between these variables as covariates.  
 
Sensitivity analyses were performed in which patients were censored at the time of first non-
fatal MI/stroke (including hemorrhagic stroke), to investigate the influence of prior 
atherosclerotic events on risk of HF hospitalization with liraglutide versus placebo.  
 
The interaction between trial treatment, HF history and heart rate was also assessed. Change 
in heart rate from baseline at 3 years was analyzed using a mixed model for repeated 
measures, which included treatment group (liraglutide or placebo), HF history at baseline, 
baseline heart rate, sex, region, antidiabetic therapy at baseline, age at baseline, the 
interaction between each of these variables and study visit, and the interaction between 
treatment group and HF history.  
 
Statistical significance was defined as p < 0.05. 
 
Results  




At baseline, 18% of patients had a history of HF (NYHA class I–III) (12); these patients were 
similarly distributed across the two treatment groups in each NYHA class (Table 1). Overall, 
most patients with HF had NYHA class II HF (Table 1). Fourteen patients with HF at 
baseline had missing NYHA category information and were included in the ‘with NYHA I–
III HF at baseline’ group (NYHA class IV HF was an exclusion criterion) (Table 1).  
Baseline characteristics were generally comparable between treatment arms, both among 
patients with and without a history of HF at baseline (Table 1). Higher proportions of patients 
with a history of HF at baseline were female and White, versus patients without a history of 
HF (Table 1). Patients with a history of HF also had a numerically shorter mean diabetes 
duration and numerically higher mean body weight, body mass index, low density lipoprotein 
cholesterol and triglycerides than those without HF (Table 1). 
Table 2 summarizes the use of cardiovascular medications (including angiotensin converting 
enzyme inhibitors, angiotensin receptor blockers, beta-blockers, loop diuretics and 
aldosterone antagonists) at baseline by history of HF and randomized treatment. The use of 
cardiovascular medications was generally balanced between treatment groups at baseline, 
with expectedly greater use of diuretics and antithrombotic medication in participants with, 
versus without, a history of HF at baseline (Table 2). The distribution of new types of 
concomitant cardiovascular medications added after baseline is also shown in Table 2. A 
numerically higher proportion of patients with, versus without, a history of HF at baseline 
initiated new antithrombotic therapy (Table 2). There was also slightly less initiation of new 
antihypertensives and diuretics in participants with a history of HF, but this may be reflective 
of higher baseline use: most patients in this group were receiving these medication classes, 
which can be used to treat HF, at baseline (Table 2). Similar proportions of patients with and 
without HF at baseline initiated new loop diuretics (Table 2). Sodium-glucose cotransporter-2 




relatively small proportions of patients in the overall population (liraglutide arm: 2.1%; 
placebo arm: 2.8%), as previously reported (12).  
Interaction between treatment group and HF history for cardiovascular events and all-
cause death  
Based on pooled data for both treatment groups, higher proportions of patients with a history 
of HF at baseline experienced cardiovascular events (except non-fatal stroke) and all-cause 
death during the trial than patients without a history of HF (Figure 1 and Table 3).  
Overall, no statistically significant interaction was detected between treatment group 
(liraglutide or placebo) and HF history for cardiovascular events or all-cause death (Figure 1).  
Effects of liraglutide versus placebo on MACE observed in the overall population (Figure 
2A) (12) were consistent in patients with a history of HF at baseline (Figures 1 and 2B) and 
those without a history of HF at baseline (p-interaction = 0.53; Figures 1 and 2C). Similar 
results were obtained for expanded MACE (p-interaction = 0.72; Figure 1).  
The risks of the three individual components of the primary composite outcome (namely non-
fatal MI, non-fatal stroke and cardiovascular death) in these patient subgroups are displayed 
in Figure 1. There was no increase in non-fatal MI or non-fatal stroke in either subgroup (p-
interaction for non-fatal MI = 0.29; p-interaction for non-fatal stroke = 0.99; Figure 1). 
Furthermore, fewer patients experienced cardiovascular death with liraglutide versus placebo, 
regardless of whether they had a history of HF at baseline or not (p-interaction = 0.50; Figure 
1).  
No increased risk of HF hospitalization was observed with liraglutide versus placebo in the 
overall population (Figure 2D) (12) or in either HF subgroup (p-interaction = 0.22; Figures 1, 




Effects of liraglutide versus placebo on the composite outcome of HF hospitalization or 
cardiovascular death observed in the overall population (Figure 2G) were consistent in 
patients with a history of HF at baseline (Figures 1 and 2H) and those without HF at baseline 
(p-interaction = 0.19; Figures 1 and 2I). Similar results were observed for all-cause death (p-
interaction = 0.63; Figures 1 and 3) and for the composite outcome of HF hospitalization or 
all-cause death (p-interaction = 0.31; Figure 1). 
Rates of MACE, HF hospitalization, all-cause death and two composite outcomes are 
presented by baseline NYHA class in Table 4. Due to the small number of patients in some of 
these subgroups, no statistical analyses were performed.  
Influence of atherosclerotic events on risk of HF hospitalization 
In the overall population, there were 275 and 304 first non-fatal MI events with liraglutide 
and placebo, respectively. There were 152 and 163 first non-fatal stroke events with 
liraglutide and placebo, respectively. Separate sensitivity analyses were conducted in which 
patients were censored at the time of first non-fatal MI/stroke, to assess whether the risk of 
HF hospitalization with liraglutide versus placebo was influenced by prior atherosclerotic 
events. In these sensitivity analyses, 396 first events of HF hospitalization were analyzed 
(compared with 466 first events of HF hospitalization in the main analyses). Results of these 
analyses were consistent with the main analyses without censoring at the time of first non-
fatal MI/stroke. Specifically, in the overall population, the HR (95% CI) for liraglutide versus 
placebo in the sensitivity analysis was 0.86 (0.71; 1.05). In patients with a history of HF (N = 
193 first events), the corresponding HR (95% CI) was 0.94 (0.71; 1.24) and in those without 
a history of HF (N = 203 first events), it was 0.79 (0.60; 1.04). Results of the main analyses 
are displayed in Figure 1.  




Based on estimated glomerular filtration rate, renal function at baseline was similar in 
patients with and without a history of HF at baseline (Table 1). 
Incidence of the pre-specified nephropathy endpoint was numerically lower in patients with a 
history of HF at baseline versus those without HF at baseline (5.2% vs 6.8%, respectively).  
There was a significantly lower risk of nephropathy with liraglutide versus placebo in the 
overall population (12). There was no statistically significant interaction between treatment 
group and history of HF at baseline for confirmed nephropathy (p-interaction = 0.95). The 
HR for confirmed nephropathy with liraglutide versus placebo was 0.77 (95% CI: 0.51; 1.18) 
in patients with a history of HF at baseline and 0.78 (95% CI: 0.66; 0.93) in patients without 
HF at baseline.  
Interaction between treatment group, HF history and heart rate 
Liraglutide was associated with an increase in heart rate versus placebo in the overall 
population (12). No statistically significant interaction was observed between treatment group 
and history of HF at baseline for change in heart rate (p-interaction = 0.16). The estimated 
treatment difference for the change in heart rate from baseline to 3 years was 2.3 beats per 
minute (95% CI: 1.2; 3.4) in patients with a history of HF at baseline and 3.1 beats per 
minute (95% CI 2.6; 3.6) in patients without HF at baseline.  
 
Discussion 
Recent European Society of Cardiology guidelines developed in collaboration with the 
European Association for the Study of Diabetes refer to cardiovascular outcomes trials of 
glucose-lowering therapies and provide recommendations based on their findings (20). The 




dulaglutide) had a neutral effect on the risk of HF hospitalization in their placebo-controlled 
randomized trials and state that these medications may be considered for diabetes treatment 
in patients with HF (20). Liraglutide is also recommended in patients with T2D and 
cardiovascular disease, or very high/high cardiovascular risk, to reduce cardiovascular events 
and the risk of death (20).  
When considering the effect of other glucose-lowering therapies on HF, the sodium-glucose 
cotransporter-2 inhibitors empagliflozin, canagliflozin and dapagliflozin have been associated 
with early and significant decreases in the risk of HF outcomes versus placebo in people with 
T2D (5,6,21-23). These medications are recommended to lower the risk of HF hospitalization 
in patients with diabetes (20). In some studies, other glucose-lowering medications have been 
associated with an increased risk of HF events or HF hospitalization in people with T2D 
(1,3,20,24,25). For this reason, thiazolidinediones (rosiglitazone and pioglitazone) and the 
DPP-4i saxagliptin are not recommended for diabetes treatment in patients at risk of HF or 
with previous HF (20). Results from the TECOS and CARMELINA cardiovascular outcomes 
trials of sitagliptin and linagliptin, respectively, do not support a class effect of DPP-4is on 
HF hospitalization, however (26,27). Sitagliptin and linagliptin have a neutral effect on HF 
hospitalization and can be considered for diabetes treatment in patients with HF (20). Overall, 
there is a need to manage cardiovascular risk in patients with T2D in an individualized 
manner. 
In this study, we investigated effects of liraglutide versus placebo on cardiovascular events, 
including HF hospitalization, all-cause death, nephropathy and heart rate, in LEADER trial 
participants, stratified by history of HF at baseline. Consistent with published results for the 
overall LEADER population (12), we report lower observed frequencies of MACE, expanded 
MACE, several individual cardiovascular endpoints, nephropathy and death with liraglutide 




risk of HF hospitalization was observed in patients randomized to liraglutide versus placebo, 
regardless of baseline HF status. No statistically significant interaction was observed between 
treatment group and history of HF at baseline for change in heart rate. Our findings support 
the recommendation that liraglutide may be considered for diabetes treatment in patients with 
HF (20).  
In other subgroup analyses of GLP-1RAs by history of HF at baseline, there were no 
significant differential treatment effects of lixisenatide, once-weekly exenatide, semaglutide 
or albiglutide on MACE (8,9,11,13). However, reductions in all-cause death and the 
composite of all-cause death or HF hospitalization with once-weekly exenatide were only 
observed in patients without baseline HF (p-interaction for the HF subgroups = 0.031 and 
0.015, respectively) (28).  
Increases in mean heart rate (generally <10 beats per minute) have been observed following 
treatment with liraglutide or other GLP-1RAs (12,29,30), which theoretically may be 
detrimental in HF (31). No increased risk of MACE or HF hospitalization was observed with 
liraglutide versus placebo in patients with heart rate increases of <10 or ≥10 beats per minute 
from baseline to 6 months in the LEADER trial (32). In the present analysis, the increase in 
heart rate with liraglutide did not seem to raise the risk for MACE or HF hospitalization, even 
in those patients with HF at baseline.  
Taken together, results from previous small studies with liraglutide in patients with HF were 
inconclusive: some showed improvements in left ventricular function (16,17), while others 
indicated potential safety concerns (18,19). For example, in the LIVE study, which assessed 
241 patients with chronic HF with reduced left ventricular ejection fraction (LVEF) with or 
without T2D, more patients experienced serious cardiac adverse events in the liraglutide 




were pooled (19). However, these events were experienced by few patients in both treatment 
groups (19). The FIGHT trial, which included 300 patients with or without T2D, who were 
recently hospitalized with HF and reduced LVEF, showed a non-significant increase in re-
hospitalization for HF with liraglutide versus placebo (18). The LIVE and FIGHT trial 
populations differed from the LEADER population, which only included patients with T2D 
and had a relatively low prevalence of HF at baseline (12). Furthermore, the LEADER 
population with HF (most of whom had NYHA class II HF) does not represent a more 
advanced HF population than the LIVE and FIGHT populations, which recruited patients 
based on LVEF criteria (≤45% and ≤40%, respectively). With a substantively larger dataset 
and much longer treatment duration compared with LIVE and FIGHT, the present analysis 
shows no increase in HF hospitalization with liraglutide versus placebo in patients with a 
history of NYHA class I–III HF and T2D.  
The risk of total (first and recurrent) HF hospitalization events occurring with liraglutide 
versus placebo in LEADER has been analyzed using three different models (33). Results 
from each of the models were consistent with the analysis of first HF hospitalization events 
(33). 
A recent meta-analysis of cardiovascular outcomes trials showed that GLP-1RAs reduced the 
risk HF hospitalization by 9%, although this reduction was not considered statistically robust 
(15). It was noted that the largest reductions in HF hospitalization were observed in the two 
trials with the greatest reductions in MI (Harmony Outcomes and LEADER), and 
hypothesized that the favorable effect in the meta-analysis could be secondary to reduction in 
MI (15). However, results of our sensitivity analyses in which patients were censored at the 
time of first non-fatal MI/stroke suggest that any effect of liraglutide to reduce HF 
hospitalization cannot be solely explained by reductions in atherosclerotic events (non-fatal 




Mechanisms underlying the observed numeric reduction in HF hospitalization with liraglutide 
versus placebo in the LEADER population are unknown, but could involve weight loss 
and/or less nephropathy with liraglutide (12). Weight reduction from baseline was 2.3 kg 
(95% CI: 2.5; 2.0) greater with liraglutide versus placebo at 36 months (12). Another 
randomized clinical trial, involving participants with obesity and clinically stable HF with 
preserved ejection fraction, showed that caloric restriction or aerobic exercise training can 
lead to weight loss and increased exercise capacity (measured as peak oxygen consumption), 
representing improvement in the primary HF symptom of exercise intolerance (34). With 
caloric restriction, improvements were observed in some, but not all, measures of cardiac 
function, suggesting that favorable ‘non-cardiac’ peripheral adaptations may accompany 
weight loss in these individuals (34). In the current analysis, liraglutide was associated with a 
lower occurrence of nephropathy versus placebo in patients with and without a history of HF 
at baseline. Whether or not these results are related to the natriuretic effects of liraglutide (35) 
is unclear.  
Finally, anti-inflammatory effects associated with GLP-1RAs, including liraglutide, may also 
have an impact on cardiac function and the pathophysiology of HF (36).  
Study limitations 
This study has several limitations. First, it relied on the accurate reporting of medical 
histories of HF and NYHA class by the trial investigators at baseline. Important clinical 
information related to HF, including LVEF (to confirm reduced or preserved ejection 
fraction), etiology of HF and biomarker data (e.g. N-terminal pro-B-type natriuretic peptide 
or troponin), was not collected during the trial. As a result, some of the participants may have 
had undiagnosed HF, particularly if they had a preserved ejection fraction (37). Additionally, 




LEADER to HF studied in other clinical trials. Second, this report was based on exploratory 
analyses, some of which were not pre-specified. Third, the analyses were not corrected for 
multiplicity. However, while multiple comparisons can increase the probability of obtaining a 
false-positive result, no interaction tests were statistically significant. Fourth, the LEADER 
trial was not powered to detect treatment interactions between subgroups. Fifth, our analyses 
may have been confounded by differences between the HF subgroups and treatment groups, 
e.g. in terms of concomitant medications received. Additionally, since LEADER included a 
patient population with T2D and high cardiovascular risk (12), our findings may not be 
applicable to patients with T2D who have a lower risk for cardiovascular events than the 
LEADER population. Finally, with NYHA class IV HF being an exclusion criterion and only 
13% of the HF subgroup having NYHA class III HF, our findings are mostly based on people 
with NYHA class I–II HF and may not be generalizable to more advanced cases of HF. 
Despite these limitations, this analysis has several strengths, including its basis on data from a 
large, multinational, double-blind cardiovascular outcomes trial, with independent 
adjudication of cardiovascular events, including HF hospitalization. 
 
Conclusions 
There was no increased risk of HF hospitalization with liraglutide versus placebo in patients 
with or without HF at baseline. Furthermore, there were lower rates of MACE, nephropathy 
and mortality with liraglutide versus placebo, irrespective of baseline HF status. Overall, 
results from this analysis of LEADER data indicate that liraglutide should be considered a 
suitable treatment option for patients with T2D, either with or without a history of HF 





Clinical perspectives  
Clinical competencies in medical knowledge 
Data regarding effects of the GLP-1 analog liraglutide in patients with T2D and HF have 
been lacking. Based on this analysis of the large LEADER patient cohort (followed for up to 
5 years [median of 3.8 years]), liraglutide appears to be an appropriate therapeutic option for 
patients with T2D and high cardiovascular risk who have a history of HF (NYHA class I–III), 
as well as those who do not have a history of HF. 
 
Translational outlook recommendations 
Further studies of liraglutide in patients with T2D and a history of HF should look at HF with 
reduced and preserved ejection fraction and report important clinical information related to 
HF, including HF etiology and biomarker data (e.g. N-terminal pro-B-type natriuretic peptide 
or troponin), with greater control of potential confounding factors. Future studies should also 
evaluate mechanisms underlying the effects of liraglutide on cardiovascular outcomes, and 
assess whether weight loss observed with liraglutide and other GLP-1RAs could be beneficial 
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Figure 1 (Central Illustration). Occurrence of CV outcomes and all-cause death, 
stratified by history of HF at baseline.  
The p value is for the interaction between treatment group and HF at baseline. CI, confidence 
interval; CV, cardiovascular; HF, heart failure; MACE, major adverse cardiovascular events; 
MI, myocardial infarction; N, number of patients with at least one event; NYHA, New York 
Heart Association; UAP, unstable angina pectoris; % proportion of patients with a first event 
between randomization and follow-up. 
 
Figure 2. First confirmed MACE (A, B and C), HF hospitalization (D, E and F) and 
composite outcome of HF hospitalization or CV death (G, H and I) by history of HF at 
baseline and randomized treatment.  
Parts A and D reproduced from N Engl J Med, Marso SP et al, Liraglutide and cardiovascular 
outcomes in type 2 diabetes, 375:311-22. Copyright© 2016 Massachusetts Medical Society. 
Reprinted with permission from Massachusetts Medical Society (12). Cumulative incidences 
estimated using the Kaplan–Meier method, and HRs using the Cox proportional-hazards 
regression model. Data analyses truncated at 54 months because <10% of patients had an 
observation time beyond 54 months. CI, confidence interval; CV, cardiovascular; HF, heart 
failure; HR, hazard ratio; MACE, major adverse cardiovascular events; NYHA, New York 





Figure 3. All-cause death by history of HF at baseline and randomized treatment. (A) 
Patients with NYHA I–III HF at baseline; (B) patients without NYHA I–III HF at 
baseline.  
Cumulative incidences estimated using the Kaplan–Meier method, and HRs using the Cox 
proportional-hazards regression model. Data analyses truncated at 54 months because <10% 
of patients had an observation time beyond 54 months. CI, confidence interval; HF, heart 





Table 1. Baseline characteristics by history of HF at baseline and randomized treatment. 
 
 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline 
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total  
(N = 7673) 
Male, N (%) 483 (57.8) 500 (60.1) 983 (59.0) 2528 (66.0) 2492 (64.9) 5020 (65.4) 
Female, N (%) 352 (42.2) 332 (39.9) 684 (41.0) 1305 (34.0) 1348 (35.1) 2653 (34.6) 
Age, years 63.5 ± 7.8 64.0 ± 7.8 63.7 (7.8) 64.4 ± 7.1 64.5 ± 7.1 64.4 ± 7.1 
Race, N (%)  
White               701 (84.0) 705 (84.7) 1406 (84.3) 2915 (76.1) 2917 (76.0) 5832 (76.0) 
Black or African American 63 (7.5) 56 (6.7) 119 (7.1) 307 (8.0) 351 (9.1) 658 (8.6) 
Asian 38 (4.6) 45 (5.4) 83 (5.0) 433 (11.3) 420 (10.9) 853 (11.1) 
Other 33 (4.0) 26 (3.1) 59 (3.5) 178 (4.6) 152 (4.0) 330 (4.3) 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline 
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total  
(N = 7673) 
Glycated hemoglobin, % 8.8 ± 1.5 8.7 ± 1.5 8.7 ± 1.5 8.7 ± 1.6 8.7 ± 1.5 8.7 ± 1.5 
Body mass index, kg/m2 34.2 ± 6.9 33.9 ± 6.8 34.0 ± 6.9 32.2 ± 6.1 32.2 ± 6.1 32.2 ± 6.1 
Body weight, kg 96.6 ± 22.4 95.3 ± 21.6 95.9 ± 22.0 90.9 ± 20.8 90.8 ± 20.5 90.8 ± 20.6 
Systolic blood pressure, mmHg 135.1 ± 18.2 134.9 ± 18.6 135.0 ± 18.4 136.1 ± 17.7 136.1 ± 17.5 136.1 ± 17.6 
Diastolic blood pressure, mmHg 77.2 ± 10.6 76.9 ± 10.2 77.1 ± 10.4 77.2 ± 10.3 77.0 ± 10.1 77.1 ± 10.2 
Heart rate, beats per minute 73.0 ± 11.4 73.1 ± 11.2 73.0 ± 11.3 72.6 ± 11.3 72.4 ± 11.5 72.5 ± 11.4 
Low density lipoprotein cholesterol, 
mmol/L 
2.5 ± 1.0 2.5 ± 1.0 2.5 ± 1.0 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 
High density lipoprotein cholesterol, 
mmol/L 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline 
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total  
(N = 7673) 
Total cholesterol, mmol/L 4.6 ± 1.2 4.6 ± 1.3 4.6 ± 1.2 4.4 ± 1.2 4.4 ± 1.1 4.4 ± 1.2 
Triglycerides, mmol/L 2.2 ± 1.5 2.2 ± 2.0 2.2 ± 1.8 2.0 ± 1.4 2.0 ± 1.6 2.0 ± 1.5 
eGFR, mL/min/1.73m2 78.4 ± 26.7 77.8 ± 26.4 78.1 ± 26.6 80.6 ± 27.7 81.2 ± 27.3 80.9 ± 27.5 
Renal function, N (%)  
Normal  
(eGFR >90 mL/min/1.73m2) 
274 (32.8) 268 (32.2) 542 (32.5) 1346 (35.1) 1387 (36.1) 2733 (35.6) 
Mild impairment  
(eGFR 60 to <90 mL/min/1.73m2) 
350 (41.9) 342 (41.1) 692 (41.5) 1582 (41.3) 1633 (42.5) 3215 (41.9) 
Moderate impairment  
(eGFR 30 to <60 mL/min/1.73m2) 
186 (22.3) 201 (24.2) 387 (23.2) 813 (21.2) 734 (19.1) 1547 (20.2) 
Severe impairment  
(eGFR <30 mL/min/1.73m2) 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline 
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total  
(N = 7673) 
NYHA class, N (%)* 
I 179 (21.4) 169 (20.3) 348 (20.9) — — — 
II 545 (65.3) 546 (65.6) 1091 (65.4) — — — 
III 108 (12.9) 106 (12.7) 214 (12.8) — — — 
Unknown 3 (0.4) 11 (1.3) 14 (0.8) — — — 
 
Full analysis set. Data are mean ± standard deviation or number of patients (percentage of patients within the relevant group). *Based on medical 
history as reported by the trial investigator for each patient. HF includes NYHA class I, II and III HF, and patients with HF at baseline who had 
missing NYHA category information. Chronic NYHA class IV HF was a LEADER trial exclusion criterion. eGFR, estimated glomerular 





Table 2. Concomitant cardiovascular medications by history of HF and randomized treatment. 
 
 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline  
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total 
(N = 7673) 
Concomitant cardiovascular medications at baseline 
Antihypertensive therapy, N (%)        812 (97.2) 798 (95.9) 1610 (96.6) 3517 (91.8) 3504 (91.3) 7021 (91.5) 
Beta-blockers 635 (76.0) 576 (69.2) 1211 (72.6) 2017 (52.6) 1953 (50.9) 3970 (51.7)  
Calcium channel blockers 260 (31.1) 244 (29.3) 504 (30.2) 1278 (33.3) 1235 (32.2) 2513 (32.8) 
Angiotensin converting enzyme 
inhibitors 
450 (53.9) 490 (58.9) 940 (56.4) 1967 (51.3) 1860 (48.4) 3827 (49.9) 
Angiotensin receptor blockers  278 (33.3) 231 (27.8) 509 (30.5) 1210 (31.6) 1255 (32.7) 2465 (32.1) 
Other antihypertensive therapies 76 (9.1) 73 (8.8) 149 (8.9) 392 (10.2) 381 (9.9) 773 (10.1) 
Diuretics, N (%) 514 (61.6) 543 (65.3) 1057 (63.4) 1439 (37.5) 1410 (36.7)  2849 (37.1) 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline  
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total 
(N = 7673) 
Thiazides 89 (10.7) 87 (10.5) 176 (10.6) 740 (19.3) 701 (18.3) 1441 (18.8) 
Thiazide-like diuretics 102 (12.2) 128 (15.4)  230 (13.8) 223 (5.8) 227 (5.9) 450 (5.9) 
Aldosterone antagonists 133 (15.9) 129 (15.5) 262 (15.7) 121 (3.2) 122 (3.2)  243 (3.2) 
 Lipid-lowering drugs, N (%) 605 (72.5) 598 (71.9) 1203 (72.2) 2959 (77.2) 2917 (76.0)  5876 (76.6) 
Statins 582 (69.7) 567 (68.1) 1149 (68.9) 2823 (73.6) 2769 (72.1) 5592 (72.9) 
Ezetimibe 21 (2.5) 17 (2.0) 38 (2.3) 144 (3.8) 152 (4.0) 296 (3.9) 
Other lipid-lowering drugs 85 (10.2) 86 (10.3) 171 (10.3)  410 (10.7) 427 (11.1) 837 (10.9)  
Platelet aggregation inhibitors, N (%) 550 (65.9) 520 (62.5) 1070 (64.2) 2655 (69.3) 2601 (67.7) 5256 (68.5) 
Acetylsalicylic acid or 
acetylsalicylate lysine 
517 (61.9) 494 (59.4) 1011 (60.6) 2460 (64.2) 2405 (62.6) 4865 (63.4) 
Clopidogrel, ticlopidine, 
prasugrel, ticagrelor  




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline  
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total 
(N = 7673) 
Antithrombotic medication, N (%) 130 (15.6) 123 (14.8) 253 (15.2) 179 (4.7) 191 (5.0) 370 (4.8) 
Vitamin K antagonists 128 (15.3) 120 (14.4) 248 (14.9) 167 (4.4) 181 (4.7) 348 (4.5) 
Direct thrombin inhibitors 2 (0.2) 3 (0.4) 5 (0.3)  15 (0.4) 9 (0.2) 24 (0.3) 
Direct factor Xa inhibitors 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (<0.1) 1 (<0.1) 
Cardiovascular medications initiated after baseline  
Antihypertensive therapy, N (%)        14 (1.7) 15 (1.8) 29 (1.7)  141 (3.7)  147 (3.8)  288 (3.8) 
Beta-blockers 6 (0.7) 7 (0.8) 13 (0.8) 60 (1.6) 58 (1.5) 118 (1.5) 
Calcium channel blockers 6 (0.7) 1 (0.1) 7 (0.4) 27 (0.7) 27 (0.7) 54 (0.7)  
Angiotensin converting enzyme 
inhibitors 
5 (0.6) 8 (1.0) 13 (0.8) 73 (1.9) 84 (2.2) 157 (2.0)  
Angiotensin receptor blockers  8 (1.0) 5 (0.6) 13 (0.8) 41 (1.1) 59 (1.5)  100 (1.3) 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline  
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total 
(N = 7673) 
Diuretics, N (%) 81 (9.7) 97 (11.7) 178 (10.7) 433 (11.3) 547 (14.2) 980 (12.8)  
Loop diuretics 59 (7.1) 59 (7.1) 118 (7.1) 244 (6.4) 320 (8.3) 564 (7.4) 
Thiazides 16 (1.9) 28 (3.4) 44 (2.6) 152 (4.0) 208 (5.4) 360 (4.7) 
Thiazide-like diuretics 15 (1.8) 22 (2.6) 37 (2.2)  58 (1.5) 71 (1.8)  129 (1.7) 
Aldosterone antagonists 26 (3.1)  29 (3.5) 55 (3.3) 91 (2.4) 64 (1.7) 155 (2.0) 
 Lipid-lowering drugs, N (%) 76 (9.1) 89 (10.7) 165 (9.9)  332 (8.7) 389 (10.1) 721 (9.4) 
Statins 64 (7.7)  79 (9.5) 143 (8.6)  306 (8.0)  368 (9.6) 674 (8.8) 
Ezetimibe 3 (0.4) 3 (0.4) 6 (0.4) 14 (0.4) 11 (0.3) 25 (0.3) 
Other lipid-lowering drugs 16 (1.9) 18 (2.2) 34 (2.0) 44 (1.1) 46 (1.2)  90 (1.2) 
Platelet aggregation inhibitors, N (%) 62 (7.4) 76 (9.1) 138 (8.3)  313 (8.2) 351 (9.1) 664 (8.7) 
Acetylsalicylic acid or 
acetylsalicylate lysine 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline  
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total 
(N = 7673) 
Clopidogrel, ticlopidine, 
prasugrel, ticagrelor  
17 (2.0)  24 (2.9) 41 (2.5) 87 (2.3) 100 (2.6) 187 (2.4) 
Antithrombotic medication, N (%) 64 (7.7) 60 (7.2) 124 (7.4) 171 (4.5) 215 (5.6) 386 (5.0) 
Vitamin K antagonists 49 (5.9) 47 (5.6) 96 (5.8) 124 (3.2) 142 (3.7) 266 (3.5) 
Direct thrombin inhibitors 5 (0.6) 5 (0.6) 10 (0.6) 27 (0.7) 30 (0.8) 57 (0.7) 
Direct factor Xa inhibitors 18 (2.2) 15 (1.8) 33 (2.0)  39 (1.0) 57 (1.5) 96 (1.3) 
 
Full analysis set. Includes patients with HF at baseline who had missing NYHA category information (N = 14). Data for cardiovascular 
medications initiated after baseline exclude patients who received a medication from the relevant class (antihypertensive therapy, diuretics, lipid-
lowering drugs, platelet aggregation inhibitors or antithrombotic medications) at baseline. N, number of patients; NYHA, New York Heart 





Table 3. Confirmed deaths by history of HF at baseline and randomized treatment. 
 
 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline 
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total  
(N = 7673) 
All-cause death 119 (14.3) 132 (15.9) 251 (15.1) 262 (6.8) 315 (8.2) 577 (7.5) 
Unknown cause of death 20 (2.4) 23 (2.8) 43 (2.6) 50 (1.3) 58 (1.5) 108 (1.4) 
Known cause of death 99 (11.9) 109 (13.1) 208 (12.5) 212 (5.5) 257 (6.7) 469 (6.1) 
Cardiovascular 56 (6.7) 65 (7.8) 121 (7.3) 93 (2.4) 132 (3.4) 225 (2.9) 
Death due to confirmed MI 5 (0.6) 7 (0.8) 12 (0.7) 12 (0.3) 19 (0.5) 31 (0.4) 
Death due to confirmed stroke 5 (0.6) 7 (0.8) 12 (0.7) 10 (0.3) 18 (0.5) 28 (0.4) 
Cardiovascular death not linked 
to a confirmed MI/stroke 
46 (5.5) 51 (6.1) 97 (5.8) 71 (1.9) 95 (2.5) 166 (2.2) 
Sudden cardiac death 17 (2.0) 22 (2.6) 39 (2.3) 34 (0.9) 52 (1.4) 86 (1.1) 




 Patients with NYHA I–III HF at baseline Patients without NYHA I–III HF at baseline 
 
Liraglutide  
(N = 835) 
Placebo  
(N = 832) 
Total 
(N = 1667) 
Liraglutide  
(N = 3833) 
Placebo  
(N = 3840) 
Total  
(N = 7673) 
Death due to HF or 
cardiogenic shock 
15 (1.8) 18 (2.2) 33 (2.0) 10 (0.3) 13 (0.3) 23 (0.3) 
Death due to 
cerebrovascular event 
2 (0.2) 1 (0.1) 3 (0.2) 2 (<0.1) 3 (<0.1) 5 (<0.1) 
Death due to other 
cardiovascular cause                
2 (0.2) 4 (0.5) 6 (0.4) 13 (0.3) 10 (0.3) 23 (0.3) 
Unclassifiable 8 (1.0) 2 (0.2) 10 (0.6) 10 (0.3) 6 (0.2) 16 (0.2) 
Non-cardiovascular 43 (5.1) 44 (5.3) 87 (5.2) 119 (3.1) 125 (3.3) 244 (3.2) 
 
Full analysis set. Data are number of patients (percentage of patients within the relevant group). HF includes NYHA class I, II and III HF, and 
patients with HF at baseline who had missing NYHA category information. Chronic NYHA class IV HF was a LEADER trial exclusion 




cardiovascular mortality endpoint. Sub-classification of cardiovascular deaths not linked to a confirmed MI/stroke was performed by the 





Table 4. Confirmed events by NYHA class at baseline and randomized treatment. 
 
 Liraglutide Placebo 
 N % E R N % E R 
No HF 
Full analysis set 3833    3840    
Patient-years of observation 14763    14707    
Confirmed MACE 466 12.2 567 3.84 524 13.6 656 4.46 
Confirmed HF hospitalization 110 2.9 158 1.07 140 3.6 205 1.39 
All-cause death 262 6.8 262 1.77 315 8.2 315 2.14 
Composite of confirmed HF hospitalization and 
cardiovascular death 
235 6.1 301 2.04 305 7.9 395 2.69 
Composite of confirmed HF hospitalization and all-
cause death  
348 9.1 420 2.84 417 10.9 520 3.54 




 Liraglutide Placebo 
 N % E R N % E R 
Full analysis set 179    169    
Patient-years of observation 672    626    
Confirmed MACE 29 16.2 33 4.91 46 27.2 57 9.10 
Confirmed HF hospitalization 21 11.7 27 4.02 16 9.5 28 4.47 
All-cause death 21 11.7 21 3.13 22 13.0 22 3.51 
Composite of confirmed HF hospitalization and 
cardiovascular death 
27 15.1 40 5.96 26 15.4 44 7.03 
Composite of confirmed HF hospitalization and all-
cause death  
35 19.6 48 7.15 31 18.3 50 7.98 
NYHA class II HF 
Full analysis set 545    546    
Patient-years of observation 1982    1984    




 Liraglutide Placebo 
 N % E R N % E R 
Confirmed HF hospitalization 68 12.5 127 6.41 74 13.6 125 6.30 
All-cause death 80 14.7 80 4.04 88 16.1 88 4.44 
Composite of confirmed HF hospitalization and 
cardiovascular death 
102 18.7 177 8.93 112 20.5 179 9.02 
Composite of confirmed HF hospitalization and all-
cause death  
127 23.3 207 10.44 138 25.3 213 10.74 
NYHA class III HF 
Full analysis set 108    106    
Patient-years of observation 393    387    
Confirmed MACE 25 23.1 32 8.15 24 22.6 25 6.47 
Confirmed HF hospitalization 19 17.6 30 7.64 16 15.1 28 7.24 




 Liraglutide Placebo 
 N % E R N % E R 
Composite of confirmed HF hospitalization and 
cardiovascular death 
28 25.9 43 10.95 24 22.6 42 10.86 
Composite of confirmed HF hospitalization and all-
cause death  
31 28.7 48 12.22 27 25.5 46 11.90 
Unknown 
Full analysis set 3    11    
Patient-years of observation 12    37    
Confirmed MACE 1 33.3 1 8.08 5 45.5 6 16.09 
Confirmed HF hospitalization 0 0.0 0 0.00 2 18.2 3 8.05 
All-cause death 0 0.0 0 0.00 4 36.4 4 10.73 
Composite of confirmed HF hospitalization and 
cardiovascular death 




 Liraglutide Placebo 
 N % E R N % E R 
Composite of confirmed HF hospitalization and all-
cause death  
0 0.0 0 0.00 5 45.5 7 18.77 
 
Full analysis set. Patients with HF at baseline who had missing NYHA category information (N = 14) are included in the ‘unknown’ group. E, 
number of events; HF, heart failure; MACE, major adverse cardiovascular events; N, number of patients; NYHA, New York Heart Association; 
R, rate of events per 100 patient-years of observation; %, proportion of patients. 
